BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Erlotinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Erlotinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03297606-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Erlotinib: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Erlotinib\, phase 2.\nStudy: Canadian Profiling and Targeted Ag
 ent Utilization Trial (CAPTUR)\nEstimated primary completion: 31 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/erlotinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03297606
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483555-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Erlotinib: Phase 1/2 readout est. (NCT06483555)
DESCRIPTION:Erlotinib\, phase 1/2\, Pancreatic Cancer.\nStudy: Basal-like P
 DAC Treated With Gemcitabine\, Erlotinib\, and Nab-paclitaxel\nEstimated p
 rimary completion: August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/erlotinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06483555
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Erlotinib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Erlotinib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DRU
 P Trial)\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/erlotinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04449874-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Erlotinib: Phase 1 readout est. (NCT04449874)
DESCRIPTION:Erlotinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Safety\, Pharmacokinetics\, and Activity of GDC-6036 Al
 one or in Combination in Participants With Advanced or Metastatic Solid Tu
 mors With a KRAS G12C Mutation\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/erlotinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04449874
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04981509-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Erlotinib: Phase 2 readout est. (NCT04981509)
DESCRIPTION:Erlotinib\, phase 2.\nStudy: Testing of Bevacizumab\, Erlotinib
 \, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/erlotinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04981509
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941310-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Erlotinib: Phase 2 readout est. (NCT07941310)
DESCRIPTION:Erlotinib\, phase 2.\nStudy: A Phase 2 Study of Bevacizumab Plu
 s Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer\nEstimated prim
 ary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/erlotinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07941310
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Erlotinib: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Erlotinib\, phase 2.\nStudy: ProTarget - A Danish Nationwide Cl
 inical Trial on Targeted Cancer Treatment Based on Genomic Profiling\nEsti
 mated primary completion: 30 April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/erlotinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997068-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20290805
DTEND;VALUE=DATE:20290806
SUMMARY:Erlotinib: Phase 2 readout est. (NCT06997068)
DESCRIPTION:Erlotinib\, phase 2.\nStudy: Methotrexate\, Erlotinib\, and Cel
 ecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a
  Rural Midwest United States Population\nEstimated primary completion: 5 A
 ugust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/erlotinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 97068
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04172779-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Erlotinib: Phase 2 readout est. (NCT04172779)
DESCRIPTION:Erlotinib\, phase 2.\nStudy: Erlotinib for Hepatocellular Carci
 noma Chemoprevention\nEstimated primary completion: June 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/erlotinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04172779
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06545695-1960@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Erlotinib: Phase 1/2 readout est. (NCT06545695)
DESCRIPTION:Erlotinib\, phase 1/2.\nStudy: Epidermal Growth Factor Receptor
  Inhibition for Keratinopathies\nEstimated primary completion: 30 June 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/erlotinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06545695
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
